Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026)
Johnson & Johnson (JNJ) posted Tax Provisions of $1.2 billion for Q2 2026, up 60.66% sequentially from $755.0 million in Q1 2026, and up 27.15% YoY from $954.0 million in Q2 2025.
Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Tax Provisions for 18 years, with the latest figure at $1.2 billion in Q2 2026.
- Quarterly Tax Provisions rose 27.15% year-over-year to $1.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.2 billion (down 11.25% YoY) and the FY2025 annual result came in at $5.8 billion, up 120.41% from the prior year.
- Tax Provisions advanced to $1.2 billion in Q2 2026 per JNJ's latest filing, from $755.0 million in the prior quarter.
- Over five years, Tax Provisions peaked at $2.6 billion in Q1 2025 and troughed at -$796.0 million in Q2 2023.
- A 5-year average of $883.0 million and a median of $885.0 million in 2022 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2023 and 2025: Tax Provisions tumbled 211.64% in 2023, then jumped 473.42% in 2025.
- Over 5 years, Tax Provisions stood at $862.0 million in 2022, then declined by 19.49% to $694.0 million in 2023, then slumped by 34.29% to $456.0 million in 2024, then sank by 132.89% to -$150.0 million in 2025, then jumped by 908.67% to $1.2 billion in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $1.2 billion, $755.0 million, and -$150.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 1.21 Bn |
| Mar 29, 2026 | 755.00 Mn |
| Dec 28, 2025 | -150.00 Mn |
| Sep 28, 2025 | 2.34 Bn |
| Jun 29, 2025 | 954.00 Mn |
| Mar 30, 2025 | 2.63 Bn |
| Dec 29, 2024 | 456.00 Mn |
| Sep 29, 2024 | 644.00 Mn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 459.00 Mn |
| Dec 31, 2023 | 694.00 Mn |
| Oct 1, 2023 | 908.00 Mn |
| Jul 2, 2023 | 930.00 Mn |
| Apr 2, 2023 | -796.00 Mn |
| Jan 1, 2023 | 1.19 Bn |
| Oct 2, 2022 | 862.00 Mn |
| Jul 3, 2022 | 1.03 Bn |
| Apr 3, 2022 | 713.00 Mn |
| Oct 3, 2021 | 182.00 Mn |
| Jul 4, 2021 | 384.00 Mn |